Serum GFAP and NfL levels in benign relapsing-remitting multiple sclerosis

●Fluid biomarkers may help clinicians to evaluate the activity and progression of MS.●Serum GFAP levels are elevated also in patients with benign disease course.●Serum NfL levels were found similar in benign and aggressive phenotype of RRMS.●Benign label for RRMS should be used cautiously, not as a...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Multiple sclerosis and related disorders 2021-11, Vol.56, p.103280-103280, Article 103280
Hauptverfasser:	Niiranen, Marja, Kontkanen, Aleksi, Jääskeläinen, Olli, Tertsunen, Hanna-Mari, Selander, Tuomas, Hartikainen, Päivi, Huber, Nadine, Solje, Eino, Haapasalo, Annakaisa, Kokkola, Tarja, Lohioja, Tarja, Herukka, Sanna-Kaisa, Simula, Sakari, Remes, Anne M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Benign multiple sclerosis Biomarker Biomarkers - blood Fingolimod Hydrochloride - therapeutic use GFAP Glial Fibrillary Acidic Protein - blood Humans Intermediate Filaments Multiple sclerosis Multiple Sclerosis, Relapsing-Remitting - blood Multiple Sclerosis, Relapsing-Remitting - drug therapy Natalizumab - therapeutic use Neurofilament Neurofilament Proteins - blood
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!